Loading
Life sciences · Journal article
Acs Omega · October 6, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Protein–protein interactions (PPIs) are central to physiological and pathophysiological processes. Identifying PPI modulators is the first step toward the development of new treatments. c-MYC (MYC), a key oncogene, interacts with NSD3S, stabilizing its structure and enhancing the oncogenic effect. In this work, we developed the NanoPCA assay in live cells in a 1536-well uHTS format to monitor the MYC/NSD3S PPI. We validated the platform by screening 12,000 compounds. The actions of several dose-dependent modulators were confirmed. Using orthogonal assays (immunoprecipitation, MYC reporter, and viability), we identified ethoxysanguinarine and withaferin A as potential negative modulators. Additionally, PPI in silico modeling and identification of key interaction points (hotspots) were performed to understand how the compounds may bind, revealing their potential ability to block the MYC/NSD3S PPI. These represent initial chemical tools that disrupt the MYC/NSD3S PPI signal in live cell assays and biochemical lysates, laying the foundation for targeted therapies against MYC/NSD3S-dependent cancers.